Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2019 Mar;124(5):668-670.
doi: 10.1161/CIRCRESAHA.119.314678.

SPEG, an Indispensable Kinase of SERCA2a for Calcium Homeostasis

Dai Kusumoto  1   2 , Shinsuke Yuasa  1 , Keiichi Fukuda  1
Affiliations
Editorial

SPEG, an Indispensable Kinase of SERCA2a for Calcium Homeostasis

Dai Kusumoto et al. Circ Res. 2019 Mar.
No abstract available

Keywords: Editorials; calcium; heart failure; humans; myocytes, cardiac.

PubMed Disclaimer

Figures

Figure.
Figure.
SPEG (striated muscle preferentially expressed protein kinase), which enhances calcium reuptake by SERCA2a (sarcoendoplasmic reticulum [SR] Ca2+ ATPase 2a) in cardiomyocytes. SPEG physically associates with SERCA2a, and SPEG-SK2 phosphorylates the Thr484 residue of SERCA2a. Thr484 SERCA2a facilitates SERCA2a oligomerization and enhances Ca2+ reuptake to SR. LTCC indicates L-type calcium channel; RyR2, ryanodine receptor 2; and SK2 domain, serine/threonine (Ser/Thr) kinase 2 domain.
See this image and copyright information in PMC

Comment on

References

    1. Kho C, Lee A, Hajjar RJ. Altered sarcoplasmic reticulum calcium cycling–targets for heart failure therapy. Nat Rev Cardiol. 2012;9:717–733. doi: 10.1038/nrcardio.2012.145. - PMC - PubMed
    1. Müller OJ, Lange M, Rattunde H, Lorenzen HP, Müller M, Frey N, Bittner C, Simonides W, Katus HA, Franz WM. Transgenic rat hearts overexpressing SERCA2a show improved contractility under baseline conditions and pressure overload. Cardiovasc Res. 2003;59:380–389. - PubMed
    1. Hajjar RJ, Zsebo K, Deckelbaum L, et al. Design of a phase ½ trial of intracoronary administration of AAV1/SERCA2a in patients with heart failure. J Card Fail. 2008;14:355–367. doi: 10.1016/j.cardfail.2008.02.005. - PubMed
    1. Greenberg B, Butler J, Felker GM, Ponikowski P, Voors AA, Desai AS, Barnard D, Bouchard A, Jaski B, Lyon AR, Pogoda JM, Rudy JJ, Zsebo KM. Calcium upregulation by percutaneous administration of gene therapy in patients with cardiac disease (CUPID 2): a randomised, multinational, double-blind, placebo-controlled, phase 2b trial. Lancet. 2016;387:1178–1186. doi: 10.1016/S0140-6736(16)00082-9. - PubMed
    1. Suckau L, Fechner H, Chemaly E, et al. Long-term cardiac-targeted RNA interference for the treatment of heart failure restores cardiac function and reduces pathological hypertrophy. Circulation. 2009;119:1241–1252. doi: 10.1161/CIRCULATIONAHA.108.783852. - PMC - PubMed

Substances